한빛사논문
- 조회606
Seong Ho Jeong, MD1,2, Hye Ryun Kim, PhD3, Jeonghun Kim, PhD4, Hankyeol Kim, MD5, Namki Hong, MD6, Jin Ho Jung, MD7, Kyoungwon Baik, MD1, Hanna Cho, MD, PhD5, Chul Hyoung Lyoo, MD, PhD5, Byoung Seok Ye, MD, PhD1, Young H. Sohn, MD, PhD1, Joon-Kyung Seong, PhD8,9 and Phil Hyu Lee, MD, PhD1,10
1Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea
2Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea
3Global Health Technology Research Center, College of Health Science, Korea University, Seoul, South Korea
4Medical & Health Device Division, Korea Testing Laboratory, Seoul, South Korea
5Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
6Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, Seoul, South Korea
7Department of Neurology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea
8School of Biomedical Engineering, Korea University, Seoul, South Korea
9Department of Artificial Intelligence, Korea University, Seoul, South Korea
10Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea
Corresponding Author: Phil Hyu Lee
Abstract
Objectives: To investigate whether dipeptidyl peptidase-4 inhibitors (DPP-4i) have beneficial effects on amyloid aggregation and longitudinal cognitive outcome in diabetic Alzheimer’s disease-related cognitive impairment (ADCI).
Methods: We retrospectively reviewed 282 patients with ADCI who had positive scan of 18F-florbetaben amyloid PET images were classified into three groups according to a prior diagnosis of diabetes and DPP-4i use: diabetic patients being treated with (ADCI-DPP-4i+, n=70) or without DPP-4i (ADCI-DPP-4i-, n=71), and non-diabetic patients (n=141). Multiple linear regression analyses were performed to determine inter-group differences in global and regional amyloid retention using standardized uptake value ratios calculated from cortical areas. We assessed the longitudinal changes in Mini-Mental State Examination (MMSE) score using a linear mixed model.
Results: The ADCI-DPP-4i+ group had lower global amyloid burden than the ADCI-DPP-4i− group (β = 0.075, SE = 0.024, p = 0.002) and the non-diabetic ADCI group (β = 0.054, SE = 0.021, p = 0.010) after adjusting for age, sex, education, cognitive status, and APOE ε4 carrier status. Additionally, the ADCI-DPP-4i+ group had lower regional amyloid burden in temporo-parietal areas than either the ADCI-DPP-4i− group or the non-diabetic ADCI group. The ADCI-DPP-4i+ group showed a slower longitudinal decrease in MMSE score (β = 0.772, SE = 0.272, p = 0.005) and memory recall sub-score (β = 0.291, SE = 0.116, p = 0.012) than the ADCI-DPP-4i− group.
Conclusions: These findings suggest that DPP-4i use is associated with low amyloid burden and favorable long-term cognitive outcome in diabetic patients with ADCI.
논문정보
- Research article
- 2021년 08월 (BRIC 등록일 2021-08-24)
- 국내 연구진
- 의약학 > 신경의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
